Alnylam Pharmaceuticals (ALNY) Gross Margin (2018 - 2026)
Alnylam Pharmaceuticals' (ALNY) quarterly Gross Margin came in at 76.9% in Q2 2026, down 475.0% YoY from 20.51% in Q2 2025, and down 6.48% on a QoQ basis from 82.22% in Q1 2026.
Alnylam Pharmaceuticals (ALNY) Gross Margin (2018 - 2026) Analysis & Trends
Alnylam Pharmaceuticals (ALNY) has 9 years of Gross Margin data on file, last reported at 76.9% in Q2 2026.
- Quarterly Gross Margin fell 475.0% year-over-year to 76.9% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 79.79% (up 70.0% YoY) and the FY2025 annual result came in at 81.77%, down 460.0% from the prior year.
- Gross Margin retreated to 76.9% in Q2 2026, from 82.22% in the prior quarter.
- In the past five years, Gross Margin ranged from a high of 89.8% in Q2 2024 to a low of 133.94% in Q1 2025.
- A 5-year average of 71.91% and a median of 83.92% in 2024 frame the typical range for Gross Margin.
- Annual changes were most pronounced in 2025 — Gross Margin plunged 22290 bps — and 2026, when it jumped 21616 bps.
- Tracing ALNY's Gross Margin over 5 years: stood at 86.22% in 2022, then declined by 3 bps to 83.63% in 2023, then decreased by 1 bps to 82.69% in 2024, then declined by 9 bps to 75.6% in 2025, then grew by 2 bps to 76.9% in 2026.
- The last three Gross Margin figures came in at 76.9% (Q2 2026), 82.22% (Q1 2026), and 75.6% (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 90.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 89.76% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 60,631,834.75% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 76.90% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 84.20% |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 80.31% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 76.90% |
| Mar 31, 2026 | 82.22% |
| Dec 31, 2025 | 75.60% |
| Sep 30, 2025 | 84.21% |
| Jun 30, 2025 | 81.64% |
| Mar 31, 2025 | 88.19% |
| Dec 31, 2024 | 82.69% |
| Sep 30, 2024 | 83.63% |
| Jun 30, 2024 | 89.80% |
| Mar 31, 2024 | 88.95% |
| Dec 31, 2023 | 83.63% |
| Sep 30, 2023 | 89.41% |
| Jun 30, 2023 | 76.37% |
| Mar 31, 2023 | 87.02% |
| Dec 31, 2022 | 86.22% |
| Sep 30, 2022 | 86.19% |
| Jun 30, 2022 | 84.86% |
| Mar 31, 2022 | 89.00% |
| Dec 31, 2021 | 86.99% |
| Sep 30, 2021 | 85.03% |